Adaptin Bio, Inc. develops biotechnology products for the treatment of cancer and other diseases. The company develops bispecific antibody-based therapies using its BRiTE Platform technology. Its BRiTE Platform uses fully human bispecific antibodies to redirect patients' T cells to recognize and destroy tumor cells and facilitate the delivery of T cell-targeting agents across the blood-brain barrier. The company's product pipeline includes APTN-101, an EGFRvIII x CD3 bispecific T cell engager designed to redirect T cells against tumors expressing a mutated form of epidermal growth factor receptor (EGFR), including glioblastoma, breast cancer, and lung cancer. The BRiTE Platform is focused on enabling access to the brain for T cell-targeting agents and supporting immunotherapeutic approaches for malignant glioma and other cancers. The company's technology platform is designed to utilize the human immune system to recognize, target, destroy, or deliver therapeutics to specific cells, including cancer cells. The company was formerly known as Centaur Bio Inc. Adaptin Bio, Inc. was incorporated in 2021 and is based in Charlotte, North Carolina.